March 20, 2025 - 10:26

Avalo Therapeutics has announced its financial results for 2024, highlighting significant updates regarding its ongoing clinical trials and organizational changes. The company is eagerly anticipating topline data from the Phase 2 LOTUS Trial of AVTX-009, which is being investigated for the treatment of hidradenitis suppurativa. This crucial data is expected to be released in 2026, marking an important milestone in Avalo's research and development efforts.
In a strategic move to bolster its leadership team, Avalo has appointed Jennifer Riley as the Chief Strategy Officer. Her expertise is expected to enhance the company's strategic direction as it navigates the complex landscape of biotechnology.
As of December 31, 2024, Avalo reported having approximately $135 million in cash reserves. This financial position is projected to provide sufficient runway into at least 2027, allowing the company to continue its focus on advancing innovative treatments for immune dysregulation.
October 30, 2025 - 01:50
Interest Rate Reduction Boosts Capital Access for Small BusinessesFor business owners, recent interest rate cuts signify a pivotal shift in the financial landscape, offering greater access to capital that might have previously been deemed too costly or...
October 29, 2025 - 05:04
Local Man Taken Into Custody Following Parking Lot Shooting IncidentAuthorities have reported the arrest of a Houma man in connection with a shooting that occurred in the parking lot of a local business. Witnesses at the scene described a chaotic situation as they...
October 28, 2025 - 08:06
Amazon Announces Historic Layoffs Affecting 30,000 EmployeesIn a significant move, Amazon is set to implement its largest corporate layoff to date, impacting approximately 30,000 employees across various divisions. This decision comes as part of a broader...
October 27, 2025 - 21:32
Meta Restructures Metaverse Division, Shifts Leadership FocusIn a significant organizational shift, Meta has announced a reorganization of its metaverse unit, which is aimed at enhancing its strategic focus on virtual reality (VR) and mobile technologies. As...